7-methyl-6,7-dihydro-5H-[1]pyrindine | 54664-57-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 7-methyl-6,7-dihydro-5H-[1]pyrindine
• 英文别名: 5H-Cyclopenta[B]pyridine, 6,7-dihydro-7-methyl-；7-methyl-6,7-dihydro-5H-cyclopenta[b]pyridine
• CAS: 54664-57-2
• 化学式: C₉H₁₁N
• 分子量: 133.193
• InChiKey: WTJXPILYFXGUHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  7-methyl-6,7-dihydro-5H-[1]pyrindine 在 盐酸 、 二异丁基氢化铝 、 N,N-二乙基氯甲酰胺 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 生成 (7-Methyl-6,7-dihydro-5H-[1]pyrindin-2-yl)-methanol
  参考文献：
  名称：

  A series of non-quinoline cysLT1 receptor antagonists: Sar study on pyridyl analogs of singulair®

  摘要：

  The structure-activity relationship of a series of styrylpyridine analogs of MK-0476 (montelukast, Singulair(R)) is described. This work has led to the identification of a number of potent and orally active cysLT(1), receptor (LTD4 receptor) antagonists including 2ab (1,-733,321) as an optimized candidate. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00051-1
• 作为产物：
  描述：

  2-phenylpropanesulfonyl azide 以9%的产率得到
  参考文献：
  名称：

  ABRAMOVITCH R. A.; HOLCOMB W. D., J. AMER. CHEM. SOC , 1975, 97, NO 3, 676-677

  摘要：

  DOI：

文献信息

• FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20180148457A1

  公开（公告）日：2018-05-31

  The present disclosure relates to compounds that are CaM Kinase inhibitors and to their use in the treatment of various disease states, including atrial fibrillation and myocardial infarction. In particular embodiments, the general structure of the compounds is given by Formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 and R 10 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及的化合物是CaM激酶抑制剂，用于治疗各种疾病状态，包括心房颤动和心肌梗死。在特定实施例中，化合物的一般结构由公式I给出：其中R1、R2、R3、R4、R5、R6、R9和R10如本文所述，涉及化合物的制备和使用方法以及含有相同化合物的药物组合物。
• [EN] ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE<br/>[FR] ÉTHERS D'ARYLPYRAZOLE EN TANT QU'INHIBITEURS DE LEUCOTRIÈNE A4 HYDROLASE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013012844A1

  公开（公告）日：2013-01-24

  The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof, wherein A1, A2, A3, L1, L2 and D are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

  本发明涉及公式I的化合物或其药用可接受的盐，其中A1、A2、A3、L1、L2和D如本文所定义。公式（I）的化合物可用作白三烯A4水解酶（LTA4H）的抑制剂，并用于治疗与LTA4H相关的疾病。本发明还涉及包含公式（I）化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，以及制备这些化合物的方法。
• [EN] COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES<br/>[FR] COMPOSÉS ET PROCÉDÉS D'INHIBITION DES HISTONES DÉMÉTHYLASES
  申请人：EPITHERAPEUTICS APS

  公开号：WO2016033169A1

  公开（公告）日：2016-03-03

  The present application relates to compounds being of Formula (I), (II), (III), (IV), (V), (VI), (Ilia), (Illb), (IIIc), (Hid), (Hie), (Illf), and (Illg). Compounds of Formula (I) have the structure: wherein Q, R1, R18, R19, M, A and Y are as defined herein. The compounds of the application can modulate the activity of histone demethylases (HDMEs), and can be useful for the prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, e.g., cancer.

  本申请涉及的化合物属于以下公式：(I)、(II)、(III)、(IV)、(V)、(VI)、(Ilia)、(Illb)、(IIIc)、(Hid)、(Hie)、(Illf)和(Illg)。公式(I)的化合物具有以下结构：其中Q、R1、R18、R19、M、A和Y的定义如本文所述。本申请的化合物可以调节组蛋白去甲基化酶（HDMEs）的活性，并可用于预防和/或治疗基因组失调参与发病机制的疾病，例如癌症。
• Reaction of 2-alkyl pyridine N-oxide derivatives with Mosher’s acyl chloride: first example of stereoselective Boekelheide rearrangement
  作者：Daniele Andreotti、Emanuele Miserazzi、Arnaldo Nalin、Alfonso Pozzan、Roberto Profeta、Simone Spada

  DOI：10.1016/j.tetlet.2010.10.020

  日期：2010.12

  functionality into alkyl group at the ortho position of N heteroaromatic rings. We have reported the first example of asymmetric Boekelheide rearrangement applied to a set of 2-alkyl-pyridine N-oxide derivatives using (R) Mosher’s acyl chloride as activator of the rearrangement to give, after hydrolysis, enantiomerically enriched 1-(2-pyridinyl)alkyl alcohol. Diastereoselectivity of the process was studied at

  用酰化剂处理2-烷基吡啶N-氧化物代表了将氧官能团引入到N个杂芳族环的邻位的烷基中的既定程序。我们已经报道了使用（R）Mosher酰氯作为重排活化剂将不对称Boekelheide重排应用于一组2-烷基吡啶N-氧化物衍生物的第一个例子，水解后得到对映体富集的1-（2-吡啶基）烷基醇。在低温下在不同溶剂中研究了该方法的非对映选择性，并得到了初步计算机模拟的支持。
• OPTICALLY ACTIVE CROSSLINKED CYCLIC SECONDARY AMINE DERIVATIVE
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US20210024547A1

  公开（公告）日：2021-01-28

  The present invention relates to the compound of formula (I) wherein p is 1 or 2, R 1 is —CF 3 or the like, R 2a , R 2b , R 3a , and R 3b are hydrogen atom or the like, X is —C(═O)—or the like, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.

  本发明涉及式（I）化合物，其中p为1或2，R1为—CF3或类似基团，R2a、R2b、R3a和R3b为氢原子或类似基团，X为—C(═O)—或类似基团，或其药学上可接受的盐。该化合物通过抑制与AF4、AF9或类似的代表性融合伴侣基因引起的MLL白血病的MLL融合蛋白与menin之间的结合而具有抗肿瘤效果。